Regarding the os Data Suggesting. That they have it & are sitting on is misinformed , wrong & missleading.
first, the dates do indicate updates soon.
required for full public disclosure is analysis of the data & completion of the data.
The FDA monitors the decemination of data. Meaning companies can't just sit on it.
Assuming we have full results, based on orriginal trial start & end dates?
I know, it is a hard & complicated process to understand.....but.
All of the results rely on people.
That being cancer patients, who may or may not be improving.
The " events" in some cases are end of life.
so , unless you know all of the trial paitents personally it is impossible to determine the status of the MBc O.S. Data.
please stop claiming opinions as if they are factual.
the additional ohase 2 trial has nothing directly to do with scheduling of in plac3 phase 2 trials.
meaning, it will not slow progress.
it can however expand the opportunities.